Vis enkel innførsel

dc.contributor.authorGussgard, Anne Margrete
dc.contributor.authorHope, Andrew
dc.contributor.authorJokstad, Asbjørn
dc.contributor.authorTenenbaum, Howard
dc.contributor.authorWood, Robert
dc.date.accessioned2014-03-20T13:46:39Z
dc.date.available2014-03-20T13:46:39Z
dc.date.issued2014
dc.description.abstractObjectives Treatment of oral mucositis (OM) is challenging. In order to develop and test useful treatment approaches, the development of reliable, reproducible and simpler methods than are currently available for assessment of OM is important. A Patient-Reported Oral Mucositis Symptom (PROMS) scale was assessed in patients with head and neck cancer to determine if the patient-reported OM experience, as determined by using the PROMS scale, correlate with OM assessed by clinician-based scoring tools. Materials and Methods Fifty patients with head and neck cancer and undergoing radiotherapy consented to participate. They were examined before cancer treatment and twice weekly during 6–7 weeks of therapy and once 4–6 weeks after therapy. Signs of OM were evaluated using the 3 clinician-based scoring tools; NCI-CTCAE v.3, the OMAS criteria and the Total VAS-OMAS. The participants' OM experiences were recorded using PROMS-questionnaires consisting of 10 questions on a visual analogue scale. Spearman rank correlation test were applied between the PROMS scale values and the clinician-determined scores. Repeated measures mixed linear models were applied to appraise the strengths of correlation at the different time points throughout the observation period. Results Thirty-three participants completed all stages of the study. The participant experience of OM using the PROMS scale demonstrates good correlations (Spearman's Rho 0.65–0.78, p<0.001) with the clinician-determined scores on the group level over all time points and poor to good correlations (Spearman's Rho -0.12–0.70, p<0.001) on the group level at different time points during and after therapy. When mouth opening was problematic, i.e. during the 6th and 7th week after commencing cancer treatment, the Spearman's Rho varied between 0.19 and 0.70 (p<0.001). Conclusion Patient experience of OM, as reported by the PROMS scale may be a feasible substitute for clinical assessment in situations where patients cannot endure oral examinations.en
dc.identifier.citationPLoS ONE (2014), vol. 9(3): e91733.en
dc.identifier.cristinIDFRIDAID 1121467
dc.identifier.doihttp://dx.doi.org/10.1371/journal.pone.0091733
dc.identifier.issn1932-6203
dc.identifier.urihttps://hdl.handle.net/10037/6000
dc.identifier.urnURN:NBN:no-uit_munin_5689
dc.language.isoengen
dc.publisherPublic Library of Science (PLoS)en
dc.rights.accessRightsopenAccess
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762en
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762en
dc.titleAssessment of Cancer Therapy-Induced Oral Mucositis Using a Patient-Reported Oral Mucositis Experience Questionnaireen
dc.typeJournal articleen
dc.typeTidsskriftartikkelen
dc.typePeer revieweden


Tilhørende fil(er)

Thumbnail
Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel